COVID-19: Rapid Antibody Screening & Saliva Testing

COVID-19 Screening Available to Residents of Bluffdale, Draper, Riverton, and Vineyard

Press Release
Published: May 15, 2020

The cities of Bluffdale, Draper, Riverton, and Vineyard are sponsoring COVID-19 antibody testing for city residents through a privately administered COVID-19 screening program. The goal of the program is to detect antibodies related to COVID-19. If individuals think they have been exposed, or just want to know if they have had COVID-19, they are invited to come and take a test.

Mayors from the participating communities released this joint statement about the project:

“We believe a central component to beating COVID-19 is to test our residents. We need to know our true infection rate so we can take actions to limit the spread, conduct contact tracing, and make future data-driven public policy decisions. We invite all our residents to consider being tested for COVID-19 antibodies as we continue to battle this virus.”

Any residents interested in being tested may sign up for an appointment online at rapidscreen.as.me, on a first-come, first-served basis. The screening costs $69.99 (may be reimbursable by health insurance plans), payable by credit or debit card at the time of booking. Appointments are booked in 30-minute increments throughout each day and conducted in a drive-thru setting. Results are provided within 15-20 minutes. The testing schedule is as follows:

  • Wednesday, May 20 – Draper
  • Thursday, May 21 – Riverton
  • Tuesday, May 26 – Draper
  • Thursday, May 28 – Bluffdale
  • Friday, May 29 – Vineyard

Testing will be conducted by Utah-based RapidScreen Solutions, LLC (RSS) using testing kits manufactured in the United States from New York-based Chembio. The test is a lateral flow blood test that has Emergency Use Authorization (EUA) from the FDA. Using a finger-stick test, a small (drop) blood sample is taken from a finger and placed on a test strip to detect two different antibodies in the subject’s blood: IgM and IgG. Positive results indicate the likelihood of a current or past COVID-19 infection.

Rapid Testing Utah for COVID19 Antibodies2

The cities of Bluffdale, Draper, Riverton, and Vineyard are sponsoring COVID-19 antibody testing for city residents through a privately administered COVID-19 screening program. The goal of the program is to detect antibodies related to COVID-19. If individuals think they have been exposed, or just want to know if they have had COVID-19, they are invited to come and take a test.

Mayors from the participating communities released this joint statement about the project:

“We believe a central component to beating COVID-19 is to test our residents. We need to know our true infection rate so we can take actions to limit the spread, conduct contact tracing, and make future data-driven public policy decisions. We invite all our residents to consider being tested for COVID-19 antibodies as we continue to battle this virus.”

Any residents interested in being tested may sign up for an appointment online at rapidscreen.as.me, on a first-come, first-served basis. The screening costs $69.99 (may be reimbursable by health insurance plans), payable by credit or debit card at the time of booking. Appointments are booked in 30-minute increments throughout each day and conducted in a drive-thru setting. Results are provided within 15-20 minutes. The testing schedule is as follows:

  • Wednesday, May 20 – Draper
  • Thursday, May 21 – Riverton
  • Tuesday, May 26 – Draper
  • Thursday, May 28 – Bluffdale
  • Friday, May 29 – Vineyard

Testing will be conducted by Utah-based RapidScreen Solutions, LLC (RSS) using testing kits manufactured in the United States from New York-based Chembio. The test is a lateral flow blood test that has Emergency Use Authorization (EUA) from the FDA. Using a finger-stick test, a small (drop) blood sample is taken from a finger and placed on a test strip to detect two different antibodies in the subject’s blood: IgM and IgG. Positive results indicate the likelihood of a current or past COVID-19 infection.

Rapid Testing Utah for COVID19 Antibodies2

FDA Authorized Saliva Testing will be used to Confirm Active COVID-19 Infection

In addition, RSS will randomly administer a saliva-based DNA test to some test subjects. Draper-based Spectrum Solutions manufactures the saliva tests that detect active COVID-19 infection, rather than detecting antibodies. Any person who tests positive for antibodies will also receive the saliva test to confirm active COVID-19 infection. The testing will be conducted in full compliance with FDA and CLIA requirements. The test results will not be diagnostic but are designed to provide valuable data about the COVID-19 infection rate. Check on the availability of diagnostic at-home COVID-19 testing options using saliva by visiting Spectrum’s website.

Spectrum Solutions SDNA-1000 Only EUA Approved Saliva Collection

© Spectrum Solutions™ SDNA-1000 Only EUA Authorized Saliva Collection Device for COVID-19 Testing | Photo Credit: Leslie Titus Bryant

Spectrum
in the News

Spectrum
in the News

Health is a dynamic state of wellbeing. Healthcare providers and researchers have long believed that changes in our saliva record our ongoing state-of-health story. This encrypted source of individual truth, and how to best use it, delivers us all a quicker path to informed decisions and treatments free of adverse reactions.

Interestingly, saliva acts as a wide resource of genomic information useful for identifying and monitoring in real-time a disease as well as its state of progression. Saliva analysis looks at the cellular level, the biologically active compounds, making it a true representative of what is clinically relevant.

Spectrum’s technically-superior saliva collection systems have not only been engineered to lead the saliva collection industry in molecular diagnostics and clinical research applications but deliver the safest, most robust biomaterial for the earliest detection and diagnosis of disease and infection.

  • Saliva provides the earliest path to critical detection and diagnosis
  • Saliva contains the entire library of proteins, hormones, antibodies, and other molecular compounds measured in routine blood tests
  • First EUA authorized saliva collection device for COVID-19 testing & authorized device for direct-to-patient at-home sample self-collection
  • Used in supervised & unsupervised sample collection LDT workflows of symptomatic & asymptomatic users
  • Pain-free, non-invasive, & safe – ideal for those needing frequent & repeat testing
  • In-device live virus inactivation at ambient temps (COVID-19 EUA validated data)
  • Eliminates hooded containment of samples arriving at the testing lab
  • No temperature-controlled storage or transport of collected saliva samples
  • Single device for DNA & viral RNA applications
  • Safest collection approach & most robust biomaterial for detecting COVID-19
  • Delivers 99.998% highest levels of testing accuracy & sensitivity
  • Formulation identifies infections at its earliest stage from as few as 200 copies/ml (lateral flow rapid tests need 10,000-20,000 copies/ml)
  • A single preserved saliva sample provides opportunity for multiple tests
  • Over two weeks of post-collection stability with no degradation in sample efficacy
  • System maintains critical bio-sample consistency
  • Mass-testing scalability & easy device integration using validated and supported processes
  • Mitigates any risk of infection throughout the testing process
  • Pinpoint life-cycle stage of active viral infection
  • Eliminates UN3373 shipping designation with clearance from USPS, FedEx, & UPS
  • Delivers the highest levels of testing accuracy using qualified extraction chemistries
Questions? Let’s Connect

How can we help?
Let’s Chat

Looking for a customized testing or life science product solution? Benefit from our experience, industry understanding, and process support.